Crescent Biopharma, Inc. (CBIO)
NASDAQ: CBIO · Real-Time Price · USD
12.02
-0.05 (-0.41%)
At close: Mar 9, 2026, 4:00 PM EDT
12.26
+0.24 (2.00%)
After-hours: Mar 9, 2026, 5:23 PM EDT
Crescent Biopharma Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 |
| Net Income | -153.94 | -71.47 |
| Depreciation & Amortization | 0.08 | - |
| Asset Writedown & Restructuring Costs | 80 | 4 |
| Stock-Based Compensation | 13.3 | 4.54 |
| Other Operating Activities | 2.4 | 0.01 |
| Change in Accounts Receivable | -18 | - |
| Change in Accounts Payable | -5 | 29.31 |
| Change in Unearned Revenue | 4.16 | - |
| Change in Other Net Operating Assets | 5.47 | 8.54 |
| Operating Cash Flow | -71.53 | -25.08 |
| Capital Expenditures | -0.92 | - |
| Sale (Purchase) of Intangibles | -72 | - |
| Investing Cash Flow | -72.92 | - |
| Total Debt Issued | - | 149.92 |
| Net Debt Issued (Repaid) | - | 149.92 |
| Issuance of Common Stock | 321.89 | 1.26 |
| Repurchase of Common Stock | -0.18 | - |
| Other Financing Activities | 1.27 | -3.04 |
| Financing Cash Flow | 322.98 | 164.14 |
| Net Cash Flow | 178.53 | 139.06 |
| Free Cash Flow | -72.45 | -25.08 |
| Free Cash Flow Margin | -668.12% | - |
| Free Cash Flow Per Share | -6.03 | -32.67 |
| Levered Free Cash Flow | -153.7 | - |
| Unlevered Free Cash Flow | -152.33 | - |
| Change in Working Capital | -13.37 | 37.85 |
Source: S&P Capital IQ. Standard template.
Financial Sources.